Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1) have demonstrated acceptable toxicity, promising clinical responses, durable di...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Weijie, Gilligan, Barbara M., Yuan, Jianda, Li, Tianhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884396/
https://www.ncbi.nlm.nih.gov/pubmed/27234522
http://dx.doi.org/10.1186/s13045-016-0277-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884396/
https://www.ncbi.nlm.nih.gov/pubmed/27234522
http://dx.doi.org/10.1186/s13045-016-0277-y

Ejemplares similares